Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
Public ClinicalTrials.gov record NCT02465437. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Study identification
- NCT ID
- NCT02465437
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Interventions
- JBT-101 Drug
- Placebo Drug
- Part B Open-Label Extension Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2015
- Primary completion
- Sep 30, 2016
- Completion
- Dec 10, 2020
- Last update posted
- Apr 20, 2021
2015 – 2020
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arthritis Association of Southern CA | Los Angeles | California | — | — |
| Stanford University | Palo Alto | California | — | — |
| John Hopkins Scleroderma Center | Baltimore | Maryland | — | — |
| Boston University Medical Center | Boston | Massachusetts | — | — |
| Rutgers University | New Brunswick | New Jersey | — | — |
| Weill Cornell Medical College | New York | New York | — | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | — | — |
| University of Texas Houston Medical School | Houston | Texas | — | — |
| University of Utah | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02465437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02465437 live on ClinicalTrials.gov.